DAprile S, Denaro S, Gervasi A, Vicario N, Parenti R
Front Cell Dev Biol. 2025; 13:1535073.
PMID: 40078366
PMC: 11897528.
DOI: 10.3389/fcell.2025.1535073.
Novak M, Majc B, Malavolta M, Porcnik A, Mlakar J, Hren M
Neurooncol Adv. 2025; 7(1):vdaf015.
PMID: 39963438
PMC: 11831694.
DOI: 10.1093/noajnl/vdaf015.
Berezovsky A, Nuga O, Datta I, Bergman K, Sabedot T, Gurdziel K
PLoS One. 2025; 20(2):e0315171.
PMID: 39919036
PMC: 11805374.
DOI: 10.1371/journal.pone.0315171.
Yang M, Han X, Li H, Du F, Feng C, Gong A
J Cancer. 2025; 16(4):1101-1117.
PMID: 39895794
PMC: 11786042.
DOI: 10.7150/jca.98452.
Jackson L, Erickson A, Camphausen K, Krauze A
Curr Oncol. 2025; 32(1).
PMID: 39851932
PMC: 11763554.
DOI: 10.3390/curroncol32010016.
Nrf2/Keap1/ARE regulation by plant secondary metabolites: a new horizon in brain tumor management.
Dewanjee S, Bhattacharya H, Bhattacharyya C, Chakraborty P, Fleishman J, Alexiou A
Cell Commun Signal. 2024; 22(1):497.
PMID: 39407193
PMC: 11476647.
DOI: 10.1186/s12964-024-01878-2.
Glioblastoma mesenchymal subtype enhances antioxidant defence to reduce susceptibility to ferroptosis.
DAprile S, Denaro S, Lavoro A, Candido S, Giallongo S, Torrisi F
Sci Rep. 2024; 14(1):20770.
PMID: 39237744
PMC: 11377710.
DOI: 10.1038/s41598-024-72024-8.
Multi-omics and pharmacological characterization of patient-derived glioma cell lines.
Wu M, Wang T, Ji N, Lu T, Yuan R, Wu L
Nat Commun. 2024; 15(1):6740.
PMID: 39112531
PMC: 11306361.
DOI: 10.1038/s41467-024-51214-y.
The Role of Mesenchymal Reprogramming in Malignant Clonal Evolution and Intra-Tumoral Heterogeneity in Glioblastoma.
Wu Q, Berglund A, Macaulay R, Etame A
Cells. 2024; 13(11.
PMID: 38891074
PMC: 11171993.
DOI: 10.3390/cells13110942.
Gene regulatory network topology governs resistance and treatment escape in glioma stem-like cells.
Park J, Hothi P, de Lomana A, Pan M, Calder R, Turkarslan S
Sci Adv. 2024; 10(23):eadj7706.
PMID: 38848360
PMC: 11160475.
DOI: 10.1126/sciadv.adj7706.
CRISPR-Cas9 library screening combined with an exosome-targeted delivery system addresses tumorigenesis/TMZ resistance in the mesenchymal subtype of glioblastoma.
Zhao J, Cui X, Zhan Q, Zhang K, Su D, Yang S
Theranostics. 2024; 14(7):2835-2855.
PMID: 38773970
PMC: 11103500.
DOI: 10.7150/thno.92703.
Comprehensive understanding of glioblastoma molecular phenotypes: classification, characteristics, and transition.
Xu C, Hou P, Li X, Xiao M, Zhang Z, Li Z
Cancer Biol Med. 2024; 21(5).
PMID: 38712813
PMC: 11131044.
DOI: 10.20892/j.issn.2095-3941.2023.0510.
TAK1 inhibition leads to RIPK1-dependent apoptosis in immune-activated cancers.
Damhofer H, Tatar T, Southgate B, Scarneo S, Agger K, Shlyueva D
Cell Death Dis. 2024; 15(4):273.
PMID: 38632238
PMC: 11024179.
DOI: 10.1038/s41419-024-06654-1.
Mechanistic insights and the clinical prospects of targeted therapies for glioblastoma: a comprehensive review.
Shen Y, Thng D, Wong A, Toh T
Exp Hematol Oncol. 2024; 13(1):40.
PMID: 38615034
PMC: 11015656.
DOI: 10.1186/s40164-024-00512-8.
GPR65 sensing tumor-derived lactate induces HMGB1 release from TAM via the cAMP/PKA/CREB pathway to promote glioma progression.
Yan C, Yang Z, Chen P, Yeh Y, Sun C, Xie T
J Exp Clin Cancer Res. 2024; 43(1):105.
PMID: 38576043
PMC: 10993467.
DOI: 10.1186/s13046-024-03025-8.
Roles of Histone H2A Variants in Cancer Development, Prognosis, and Treatment.
Lai P, Chan K
Int J Mol Sci. 2024; 25(6).
PMID: 38542118
PMC: 10969971.
DOI: 10.3390/ijms25063144.
A longitudinal single-cell and spatial multiomic atlas of pediatric high-grade glioma.
Sussman J, Oldridge D, Yu W, Chen C, Zellmer A, Rong J
bioRxiv. 2024; .
PMID: 38496580
PMC: 10942465.
DOI: 10.1101/2024.03.06.583588.
"Tumor Treating Fields" delivered via electromagnetic induction have varied effects across glioma cell lines and electric field amplitudes.
Ravin R, Cai T, Li A, Briceno N, Pursley R, Garmendia-Cedillos M
Am J Cancer Res. 2024; 14(2):562-584.
PMID: 38455403
PMC: 10915321.
Subtype Transdifferentiation in Human Cancer: The Power of Tissue Plasticity in Tumor Progression.
Fedele M, Cerchia L, Battista S
Cells. 2024; 13(4.
PMID: 38391963
PMC: 10887430.
DOI: 10.3390/cells13040350.
Divergent transcriptomic signatures from putative mesenchymal stimuli in glioblastoma cells.
Hart W, Myers P, Purow B, Lazzara M
Cancer Gene Ther. 2024; 31(6):851-860.
PMID: 38337036
PMC: 11192628.
DOI: 10.1038/s41417-023-00724-w.